152 related articles for article (PubMed ID: 20508610)
1. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
Guièze R; Renneville A; Cayuela JM; Abdelali RB; Boissel N; de Botton S; Rubio MT; Mazingue F; Macintyre EA; Cheok M; Sigaux F; Fenaux P; Dombret H; Preudhomme C
Leukemia; 2010 Jul; 24(7):1386-8. PubMed ID: 20508610
[No Abstract] [Full Text] [Related]
2. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy.
Doubek M; Brychtova Y; Berkovcova J; Krejci M; Palasek I; Dvorakova D; Mayer J
Leukemia; 2005 May; 19(5):885-8. PubMed ID: 15744338
[No Abstract] [Full Text] [Related]
5. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
6. Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).
Kurata K; Yamamoto K; Okazaki Y; Noguchi Y; Matsui K; Matsumoto H; Inui Y; Yakushijin K; Ito M; Nakamachi Y; Matsuoka H; Saegusa J; Minami H
Cancer Genet; 2020 Feb; 241():72-76. PubMed ID: 31353165
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
[TBL] [Abstract][Full Text] [Related]
9. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
[TBL] [Abstract][Full Text] [Related]
10. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
12. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
Tang FF; Xu LP; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Yan CH; Sun YQ; Mo XD; Liu KY; Huang XJ
Br J Haematol; 2018 Feb; 180(3):448-451. PubMed ID: 27650511
[No Abstract] [Full Text] [Related]
14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
15. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
[No Abstract] [Full Text] [Related]
16. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
17. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia.
Yoo SJ; Chi HS; Jang S; Seo EJ; Seo JJ; Lee JH; Park HS; Park CJ
Haematologica; 2005 Nov; 90(11):1493-501. PubMed ID: 16266896
[TBL] [Abstract][Full Text] [Related]
18. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
20. The NDE1 gene is disrupted by the inv(16) in 90% of cases with CBFB-MYH11-positive acute myeloid leukemia.
Van der Reijden BA; Massop M; Simons A; de Witte T; Breuning M; Jansen JH
Leukemia; 2010 Apr; 24(4):857-9. PubMed ID: 20072148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
